Outset Medical appoints Edwards Lifesciences exec Katie Szyman to board of directors

[ad_1]

Katie Szyman Edwards Outset MedicalOutset Medical (NSDQ:OM) introduced that it appointed Edwards Lifesciences government Katie Szyman to its board of administrators.

Szyman currently serves as corporate VP & GM of critical care at Edwards, having spent greater than 30 years in management roles within the medtech area, in line with a information launch. A lot of her expertise got here in 23 years at medtech big Medtronic.

She held finance roles earlier than turning into CFO of Medtronic’s coronary stent enterprise, then working with mergers and acquisitions earlier than transferring into normal administration work. Her closing position at Medtronic was president of its diabetes enterprise.

“Katie’s spectacular monitor report of ushering medical system corporations via market enlargement and excessive development is ideally suited to Outset,” Outset Medical CEO Leslie Trigg said within the launch. “Her industrial development acumen each within the vital care and client diabetes area displays our deal with remodeling the dialysis expertise for sufferers and suppliers in each the acute and residential setting.”

At Edwards, Szyman has grown the vital care enterprise by practically 50% to $800 million over simply six years, having produced related success at Medtronic, the place she grew the worldwide diabetes enterprise by greater than 40% to $1.5 billion over 5 years heading up that division.

Szyman additionally serves on the board of administrators at Inari Medical and the American Coronary heart Affiliation of Orange County. She can be on the board of governors at Opus Faculty of Enterprise on the College of St. Thomas.

“I’ve spent most of my profession targeted on improvements round affected person care, and I’ve witnessed firsthand the affect medical expertise can have on individuals’s lives,” Szyman stated. “Outset shouldn’t be solely main the cost relating to reimagining dialysis for each sufferers and suppliers but in addition catalyzing change in all the dialysis care supply mannequin. The corporate’s speedy development and aspirational targets are driving a shift available in the market, and my objective is to assist speed up that.”

[ad_2]

Source link

Related posts

Leave a Comment